Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition

被引:9
作者
Schmidt, U
Han, RO
DiSalvo, TG
Guerrero, JL
Gold, HK
Zapol, WM
Bloch, KD
Semigran, MJ
机构
[1] Massachusetts Gen Hosp, Div Cardiol, Dept Anesthesia & Crit Care, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Med, Cardiovasc Res Ctr, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
关键词
D O I
10.1016/S0735-1097(01)01270-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to evaluate the ability of type 5 phosphodiesterase (PDE5) inhibitors to augment the antithrombotic effects of inhaled nitric oxide (NO) in a canine model of platelet-mediated coronary thrombosis after thrombolysis. BACKGROUND Type 5 phosphodiesterase inhibitors potentiate the ability of NO to inhibit platelet aggregation in vitro by preventing platelet cyclic guanosine monophosphate catabolism. We previously reported that breathing low concentrations of NO gas attenuated, but did not prevent, cyclic flow reductions (CFRs) in a canine model of coronary thrombosis after thrombolysis. METHODS Cyclic flow reductions were induced after creation of a left anterior descending coronary artery stenosis, endothelial injury, thrombus formation and thrombolysis. Dogs were either untreated or treated with inhaled NO (20 ppm by volume), intravenous zaprinast, intravenous dipyridamole or the combination of inhaled NO with either PDE5 inhibitor (n = 4 per group). RESULTS Cyclic flow reductions ceased, and complete coronary patency was achieved in all dogs after they breathed NO combined with zaprinast (by 12.0 +/- 4.7 min [mean +/- SEM]) or dipyridamole (by 9.8 +/- 4.7 min). The frequency of CFRs was unaffected by NO, dipyridamole or zaprinast alone. Systemic arterial blood pressure and bleeding time were unchanged with any treatment. Ex vivo thrombin-induced platelet aggregation in dogs breathing NO and receiving dipyidamole was reduced by 75 +/- 7% (p < 0.05). CONCLUSIONS The PDE5 inhibitors potentiated the antithrombotic properties of inhaled NO in a canine model of platelet-mediated coronary artery thrombosis after thrombolysis, without prolonging the bleeding time or causing systemic hypotension. (J Am Coll Cardiol 2001;37:1981-8) (C) 2001 by the American College of Cardiology.
引用
收藏
页码:1981 / 1988
页数:8
相关论文
共 31 条
[1]   Inhaled nitric oxide increases coronary artery patency after thrombolysis [J].
Adrie, C ;
Bloch, KD ;
Moreno, PR ;
Hurford, WE ;
Guerrero, JL ;
Holt, R ;
Zapol, WM ;
Gold, HK ;
Semigran, MJ .
CIRCULATION, 1996, 94 (08) :1919-1926
[2]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1488
[3]   DIPYRIDAMOLE POTENTIATES THE ANTI-AGGREGATING AND VASODILATOR ACTIVITY OF NITRIC-OXIDE [J].
BULT, H ;
FRET, HRL ;
JORDAENS, FH ;
HERMAN, AG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 199 (01) :1-8
[4]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[5]   Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates [J].
Cheung, PY ;
Salas, E ;
Etches, PC ;
Phillipos, E ;
Schulz, R ;
Radomski, MW .
LANCET, 1998, 351 (9110) :1181-1182
[6]   PLATELETS AND THROMBOLYTIC THERAPY [J].
COLLER, BS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (01) :33-42
[7]   Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A [J].
Fawcett, L ;
Baxendale, R ;
Stacey, P ;
McGrouther, C ;
Harrow, I ;
Soderling, S ;
Hetman, J ;
Beavo, JA ;
Phillips, SC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3702-3707
[8]  
FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247
[9]   A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials [J].
Folts, JD ;
Schafer, AI ;
Loscalzo, J ;
Willerson, JT ;
Muller, JE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (02) :295-303
[10]   ENDOGENOUS NITROGEN-OXIDES AND BRONCHODILATOR S-NITROSOTHIOLS IN HUMAN AIRWAYS [J].
GASTON, B ;
REILLY, J ;
DRAZEN, JM ;
FACKLER, J ;
RAMDEV, P ;
ARNELLE, D ;
MULLINS, ME ;
SUGARBAKER, DJ ;
CHEE, C ;
SINGEL, DJ ;
LOSCALZO, J ;
STAMLER, JS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :10957-10961